Clinical Trials Logo

Recurrent Marginal Zone Lymphoma clinical trials

View clinical trials related to Recurrent Marginal Zone Lymphoma.

Filter by:

NCT ID: NCT00096005 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Start date: November 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of giving tanespimycin together with bortezomib in treating patients with advanced solid tumors or lymphomas. (Accrual for lymphoma patients closed as of 11/27/09) Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop cancer cells from dividing so they stop growing or die. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of tanespimycin by making cancer cells more sensitive to the drug. Combining tanespimycin with bortezomib may kill more cancer cells.

NCT ID: NCT00089076 Terminated - Clinical trials for Recurrent Mantle Cell Lymphoma

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

Start date: June 2004
Phase: Phase 1/Phase 2
Study type: Interventional

Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop cancer cells from growing. This phase I/II trial is studying the side effects and best dose of MDX-010 and to see how well it works in treating patients with recurrent or refractory B-cell non-Hodgkin's lymphoma.

NCT ID: NCT00060112 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Start date: March 2003
Phase: Phase 1
Study type: Interventional

Drugs used in chemotherapy such as gemcitabine use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of gemcitabine by making cancer cells more sensitive to the drug. This phase I trial is studying the side effects and best dose of oblimersen and gemcitabine in treating patients with metastatic or unresectable solid tumors or lymphoma

NCT ID: NCT00019708 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Start date: June 1999
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of geldanamycin analogue in treating patients who have advanced solid tumors or non-Hodgkin's lymphoma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00012298 Terminated - Clinical trials for Recurrent Small Lymphocytic Lymphoma

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Start date: April 2001
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal antibody therapy and rituximab with and without filgrastim and interleukin-11 in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. Biological therapies such as filgrastim and interleukin-11 use different ways to stimulate the immune system and stop cancer cells from growing.

NCT ID: NCT00005950 Terminated - Clinical trials for Recurrent Small Lymphocytic Lymphoma

506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma

Start date: April 2000
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or T-cell lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die

NCT ID: NCT00005786 Terminated - Clinical trials for Recurrent Small Lymphocytic Lymphoma

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

Start date: January 2001
Phase: N/A
Study type: Interventional

Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory lymphoma or leukemia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die